How pharmaceutical wholesalers can prevent compliance risks
Combing the provincial drug regulatory departments website publicized the revocation of the "Drug Certification of Quality Management Practice" announcement found that a significant number of drug wholesale enterprises due to illegal sales of drugs, to units or individuals who do not have legal qualifications to provide drugs and other illegal acts, the regulatory authorities identified as not operating in accordance with the law, thus being revoked certificate. The author believes that the root cause of the above problems lies in the failure of pharmaceutical wholesalers to seriously carry out compliance management and compliance risk prevention, that is, the failure to establish a compliance management system suitable for business operations.
Drug wholesale enterprises to establish compliance system, compliance management, to prevent possible compliance risks, first of all, to clarify the laws and regulations, standards, contracts and other provisions of the obligations to be performed by enterprises; in the process of drug sales, laws and regulations should be identified on the restrictive provisions of drug wholesale enterprises to sell drugs.
Looking for chemical products? Let suppliers reach out to you!
2026-07-05
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
NHU and Sinopec Advance Liquid Methionine Project
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
-
Lilly’s Mounjaro Enters China’s State Insurance System
Recommend Reading
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
Lanxess Q2 Profit Slides 17 Percent Sales Down 12.6 Percent as Global Slowdown Bites
-
Supply Chain Resilience Reshapes Chemical Competition: What Lies Behind BASF’s Stable Outlook
-
Shengquan Group H1 Profit Jumps 51 Percent Revenue Hits 5.35 Billion Yuan AI and EV Boom Drive New Materials Surge
-
Negative Factors Weighing Down, Hydrogen Peroxide Market Prices Decline Weakly in June
-
China National Chemical Signs 2711 Contracts Worth 224.8 Billion Yuan by July Landmark Green Ammonia and Overseas Projects Highlighted